Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 6, 2008, Pages 2263-2265

  Cleary, John D ^a   Garcia Effron, Guillermo ^b   Chapman, Stanley W ^a   Perlin, David S ^b  

^a UNIVERSITY OF MISSISSIPPI   (United States)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; CASPOFUNGIN; FLUCONAZOLE; MICAFUNGIN; VORICONAZOLE;

AGED; ANTIFUNGAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; BLOOD CULTURE; CANDIDA GLABRATA; CASE REPORT; FATALITY; FEMALE; FKS1 GENE; FKS2 GENE; FUNGAL GENE; FUNGAL STRAIN; HUMAN; INVASIVE CANDIDIASIS; LOADING DRUG DOSE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RECURRENT INFECTION; SEQUENCE ALIGNMENT;

AGED; ANTIFUNGAL AGENTS; CANDIDA GLABRATA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FATAL OUTCOME; FEMALE; FUNGAL PROTEINS; FUNGEMIA; GLUCOSYLTRANSFERASES; HUMANS; MEMBRANE PROTEINS; MICROBIAL SENSITIVITY TESTS; MUTATION;

EID: 44449153708     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01568-07     Document Type: Article

References (16)

1. Baixench, M. T., N. Aoun, M. Desnos-Ollivier, et al. 2007. Acquired resistance to echinocandins in Candida albicans: case report and review. J. Antimicrob. Chemother. 59:1076-1083.
2. Dodgson, A. R., C. Pujol, D. W. Denning, D. R. Soll, and A. J. Fox. 2003. Multilocus sequence typing of Candida glabrata reveals geographically enriched clades. J. Clin. Microbiol. 41:5709-5717.
3. Ernst, E. J., J. G. Miller, R. Peson, M. J. Klevay, M. Pfaller, and D. J. Diekema. 2006. Risk factors for C. glabrata bloodstream infection: a case control study, abstr. M897. Abstr. 18th Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
4. Hakki, M., J. F. Staab, and K. A. Marr. 2006. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob. Agents Chemother. 50:2522-2524.
5. Johnson, M. D., and J. R. Perfect. 2003. Caspofungin: first approved agent in a new class of antifungals. Expert Opin. Pharmacother. 4:807-823.
6. Kahn, J. N., G. Garcia-Effron, M. J. Hsu, S. Park, K. A. Marr, and D. S. Perlin. 2007. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob. Agents Chemother. 51:1876-1878.
7. Katiyar, S., M. Pfaller, and T. Edlind. 2006. Candida albicans and Candida glabrata clinical isolates exhibiting reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 50:2892-2894.
8. Krogh-Madsen, M., M. C. Arendrup, L. Heslet, and J. D. Knudsen. 2006. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis. 42:938-944.
9. Laverdiere, M., R. G. Lalonde, J. G. Baril, D. C. Sheppard, S. Park, and D. S. Perlin. 2006. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother. 57:705-708.
10. Miller, C. D., B. W. Lomaestro, S. Park, and D. S. Perlin. 2006. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy 26:877-880.
11. Moudgal, V., T. Little, D. Boikov, and J. A. Vazquez. 2005. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob. Agents Chemother. 49:767-769.
12. National Committee for Clinical Laboratory Standards. 2002. Reference method for broth dilution antifungal susceptibility testing of yeasts. Approved standard M27-A2, 2nd ed. National Committee for Clinical Laboratory Standards, Wayne, PA.
13. Park, S., R. Kelly, J. N. Kahn, et al. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49:3264-3273.
14. Pelletier, R., I. Alarie, R. Lagace, and T. J. Walsh. 2005. Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. Med. Mycol. 43:559-564.
15. Perlin, D. S. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10:121-130.
16. Pfaller, M. A., L. Boyken, R. J. Hollis, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2006. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance. J. Clin. Microbiol. 44:760-763.